Cost effectiveness acceptability curves for base case vaccination programme (girls aged 12 years only, quadrivalent vaccine, 80% coverage) under different assumptions about duration of protection from vaccine

Abstract

Incremental cost effectiveness of vaccination compared with no vaccination option is shown. Region of £20 000- £30 000 per QALY gained is shaded. Thick solid and dashed lines indicate cost effectiveness acceptability curves when considering vaccine type cervical cancers in a screened population, medium solid and dashed lines indicate curves assuming 80% coverage in screened and unscreened populations, and thin solid and dashed lines indicate curves assuming 80% coverage in screened and unscreened populations, protection against non-cervical cancers, and some cross protection against non-vaccine types<p><b>Copyright information:</b></p><p>Taken from "Economic evaluation of human papillomavirus vaccination in the United Kingdom"</p><p></p><p>BMJ : British Medical Journal 2008;337():-.</p><p>Published online 31 Jul 2008</p><p>PMCID:PMC2500202.</p><p></p

    Similar works

    Full text

    thumbnail-image

    Available Versions